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Abstract
Background: The optimum age for measles vaccination varies from country to country and thus
a standardized vaccination schedule is controversial. While the increase in measles vaccination
coverage has produced significant changes in the epidemiology of infection, vaccination schedules
have not been adjusted. Instead, measures to cut wild-type virus transmission through mass
vaccination campaigns have been instituted. This study estimates the presence of measles
antibodies among six- and nine-month-old children and assesses the current vaccination
seroconversion by using a non invasive method in Maputo City, Mozambique.
Methods: Six- and nine-month old children and their mothers were screened in a cross-sectional
study for measles-specific antibodies in oral fluid. All vaccinated children were invited for a follow-
up visit 15 days after immunization to assess seroconversion. 
Results: 82.4% of the children lost maternal antibodies by six months. Most children were
antibody-positive post-vaccination at nine months, although 30.5 % of nine month old children had
antibodies in oral fluid before vaccination. We suggest that these pre-vaccination antibodies are due
to contact with wild-type of measles virus. The observed seroconversion rate after vaccination was
84.2%. 
Conclusion: These data indicate a need to re-evaluate the effectiveness of the measles
immunization policy in the current epidemiological scenario.
Background
Measles elimination is one of the major global public
health priorities [1]. While half of the world is close to
eliminating measles, many countries in Sub-Saharan
Africa (SSA) are still struggling to control the disease [2].
In Mozambique, the measles vaccine was introduced in
1979 through an immunization campaign that targeted
children between the ages of six months to three years.
The Expanded Programme on Immunization (EPI) started
in 1981 [3]. Since then, the main intervention for measles
control in Mozambique has been the routine administra-
tion of a single dose of measles vaccine. Additionally, in
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adopted fourth yearly national vaccination campaigns tar-
geting children younger than 14 years. Despite these
efforts to increase vaccination coverage, measles epidem-
ics continue to occur periodically [4].
The increase in measles vaccination coverage in the devel-
oping world has produced significant changes in the epi-
demiology of the infection [5], such as a shift to a higher
incidence of measles in older children and young adults
[6]. Moreover, a significant proportion of women at the
reproductive age may now have measles immunity as a
result of vaccination. When compared to women who had
natural infection, vaccinated women are expected to have
lower titres of measles antibodies and give birth to off-
spring that remain passively protected against the measles
virus for a shorter period of time [7,8].
In most SSA countries, the change in the epidemiology of
infection has not been accompanied by an adjustment in
vaccination schedules. Instead, measures to cut wild- virus
transmission through mass vaccination campaigns have
been instituted [9-11]. In parallel, some countries have
started to report the consequences of mass vaccination on
the passive immunity against measles in infants and to re-
evaluate the efficacy of current vaccination schedules in
light of the new epidemiological scenario [12]. The data
obtained from these studies will prove crucial in design-
ing public health interventions for measles control and
elimination [13].
Epidemiological studies on wild-type-virus or vaccine-
induced immunity have classically been performed
through the detection of measles-specific IgG and IgM in
serum or plasma [14,15]. The use of these biological spec-
imens under field conditions in resource-poor-settings
has posed critical logistical challenges to the implementa-
tion and success of epidemiological studies and surveys
[15]. Hence, the detection of measles-specific antibodies
in oral fluid samples has been recommended as a safe,
effective and non-invasive alternative to serum and/or
plasma for the diagnosis of disease and immune surveil-
lance in Africa [16,17].
In this study, the detection of measles-specific antibodies
in oral fluid was employed to: 1) assess the level of passive
immunity against measles among six- and nine-month-
old infants, and 2) evaluate the immune response against
measles vaccine in nine-month-old infants.
Methods
Population and study design
This study was conducted in Maputo City, the capital of
Mozambique, which has an estimated population of 1.5
million people. Health services in Maputo are organized
in three districts, each served by several health-centres and
a general hospital. Health-centres offer a free health pro-
gram for all children under the age of five-years. The pro-
gram includes immunization, growth monitoring and
nutritional rehabilitation.
Subjects were recruited at the Xipamanine health-centre
and the 1° de Junho health-centre located in the urban
districts number four and two of Maputo City. The urban
districts number four and two have 300,703 and 534,744
inhabitants and reported measles vaccine coverage of 80%
and 83%, respectively (district midterm reports to MoH,
unpublished document, 2005).
The study was performed between June and September
2005, just before the 2005 measles national mass vaccina-
tion campaign. According to the EPI schedule in Mozam-
bique, children are routinely immunized with a single
dose of standard titre measles vaccine at nine months of
age. At the time when the study was conducted, the mea-
sles vaccine in use was based on Edmonston-Zagreb strain
(E-Z). Mothers of six-month-old children coming for
growth monitoring and of nine-month-old children visit-
ing the health-centre for measles immunization were
invited to participate in the study. All children and their
respective mothers were screened in a cross-sectional
study for measles-specific antibodies in oral fluid. Addi-
tionally, all children at nine-months of age were invited to
donate a second specimen of oral fluid during a follow-up
visit 15 days after vaccination.
This study was approved by the Mozambican Health
Bioethics Committee. Informed consent was obtained by
a signature or finger print from mothers after explaining
the project aims, the procedures for data and specimen
collection, and the need to return for post-vaccination
control among those vaccinated.
Data collection and definitions
Data was collected using a structured questionnaire. The
age of each child was calculated from the date of birth
recorded on the Road-to-Health Card. The age of the
mother was based on her verbal statement. A birth was
considered to be premature if the baby was born at less
than 37 weeks of gestation. This information was col-
lected from the mother's Pregnancy-Monitoring Card. A
baby with a birth weight less than 2,500 grams was
defined as having low-birth-weight. This information was
collected from the Road-to-Health Card.
On admission, the children were weighed (grams) and
measured (centimetres). The anthropometric indices
weight-for-age, height-for-age and weight-for-height were
compared with mean Z-scores to access the nutritional
status of the children. Minus two Z-scores were used asPage 2 of 8
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The immunization status of the mothers was confirmed
by the Road-to-Health Card when possible. A verbal his-
tory of immunization of the mother with no card for con-
firmation was categorized as a "history of immunization".
Mothers with no knowledge of their past immunization
were classified as having an "unknown" status. A past his-
tory of measles disease in the infant and in the mother was
collected by verbal history using the World Health Organ-
ization case definition [18]. The mother's reproductive
history was collected from the last gestation Pregnancy-
Monitoring Card retained by the mother. Verbal informa-
tion was not considered.
Sample collection and processing
Oral fluid was collected using the OraSure device
(OraSure Technologies, Bethlehem, PA, USA). The collec-
tion device consists of a 3 cm × 1 cm flat pad of absorbent
material supported by a 10 cm plastic stick. This device is
supplied with a tube containing transport buffer and a
preservative [19,20]. The absorbent pad was moved gently
4–10 times along the gums and left stationary between
the lower gum and buccal membrane for a minimum of
two minutes or until the pad was saturated with oral fluid.
Thereafter, the collection device was placed in the pre-
coded tube containing the buffer. The pads with oral fluid
samples were transported to the laboratory at the Instituto
Nacional de Saúde every day. There, tubes were centri-
fuged at 2000 rpm for five minutes. The fluid was then
transferred into a screw-capped vial and stored at -20°C
until testing.
Screening method
Oral fluid specimens were screened for measles-specific
IgG and IgM using the MicroImmune® test (MicroImmune
Ltd, UK). Both assays are capture EIAs and clasiify anti-
body status as positive, negative and borderline. The IgM
test has a reported sensitivity and specificity of 100.0%
(95% CI 85.2–100.0) and 96.6% (95% CI 90.7–99.3),
respectively [17]. The sensitivity and specificity of the IgG
assay are 97.5% (95% CI 96.1–98.3) and 86.7% (95% CI
78.4–91.5), respectively [16,21].
Data analysis
Proportions and chi-square were used as a statistical test at
a 5% significance level. The differences in mothers' ages
were assessed by one way analysis of variance.
Statistical procedures were performed using the Statistical
Package for the Social Sciences (SPSS) version 15.0. Sero-
conversion was expressed as the proportion of seronega-
tive children before vaccination who became positive for
measles-specific antibody (IgM and IgG) 15 days after vac-
cination. The statistical difference in the proportions was
compared using chi-square test with a 5% significance
level. Samples with borderline results were excluded from
this analysis.
Results
A total of 211 six-month-old children and 301 nine-
month-old infants, and their respective mothers, were
enrolled in the study. Of all nine-month-old infants
invited for the follow-up visit, 198 (65.8%) returned for
antibody testing 15 days after immunization.
Measles-specific antibodies in six-month-old infants
Only 26 (12.3%) out of 211 six-month-old infants tested
positive for measles IgG, while 174 (82.4%) tested nega-
tive for IgG and 11 (5.2%) were borderline (Table 1). Two
out of the 26 infants who tested positive for IgG also
tested positive for IgM, indicating a possible recent expo-
sure to the virus.
Table 1: IgG In oral fluid among six- and nine-month-old infants before receiving standard dose Edmonston-Zagreb vaccine
Mothers Six-month-old infants Nine-month-old infants
IgG Age
(yrs)*
Pos %
(95%CI)
Neg %
(95%CI)
BL %
(95%CI)
Pos %
(95%CI)
Neg %
(95%CI)
BL %
(95%CI)
Total
Pos 24 23 14.4 
(9.8–20.7)
128 80.5 
(73.3–86.1)
8 5 (2.3–10) 78 31.9 
(26.2–38.2)
153 62.7 
(56.2–68.7)
13 5.3 
(2.9–9.1)
403
Neg 22 3 7.3 
(2.5–19.4)
35 85.3 
(70.1–93.9)
3 7.3 
(1.9–21)
9 21.4 
(11.7–35.9)
32 76.1 
(61.4–86.5)
1 2.3 
(0.4–12.3)
83
BL 23 0 - 11 100 
(67.8–100)
0 - 3 33.3 
(12.1–64.5)
6 66.6 
(35.4–87.9)
0 - 20
Missing 6
Total 26 174 11 90 191 14 512
*median value
Pos – Positive; Neg – Negative, BL – Borderline valuePage 3 of 8
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measles IgG were born to mothers with measles IgG in
oral fluid. The remaining three infants (11.5%) were born
to IgG-negative mothers, suggesting that these infants had
been in contact with the measles virus. All these three
infants were IgM-negative.
None of the children had active clinical measles, a past
history of measles or a known contact with anybody in the
family or living in the neighbourhood with active mea-
sles. The mothers' ages ranged from 17–41 years for mea-
sles IgG-positive infants, 16–45 years for measles IgG-
negative infants and 16–37 years for the borderline
infants.
Measles-specific antibodies in nine-month-old infants
Among the 301 nine-month-old infants included in the
study, six children were not tested due to lack of a suffi-
cient volume of oral fluid. Of the 295 children that were
tested, a surprisingly high number 90 (30.5%) were posi-
tive for measles-specific IgG, while 191 (64.7%) tested
negative for IgG and 14 (4.7%) were borderline. Among
the 90 IgG-positive infants, 79 had sufficient quantity of
oral fluid for IgM testing. Five of the tested specimens
(6.3%) were simultaneously positive for IgM and IgG,
suggesting recent contact with the measles virus.
Seventy eight (86.6%) of the 90 infants positive for mea-
sles IgG were born to mothers with measles IgG in oral
fluid (Table 1). However, nine (10.0%) of the infants were
born to IgG-negative mothers. From these nine infants,
five were IgM-positive. Only one of these five children was
exposed to a family member (an older sister) with mea-
sles. With this exception, none of the other children had
active clinical measles, a past history of measles or a
known contact with anybody from the family or living in
the neighbourhood with active measles.
The mothers' ages ranged from 16–41 years for measles
IgG-positive infants, 16–44 years for measles IgG-negative
infants and 18–42 years for the borderline infants.
Factors associated with the presence of measles-specific 
antibodies in six- and nine-month-old infants
Age of the mother
The mean age for mothers included in the study was 25
years (range 16–45 years). None of the mothers could
document their vaccination status. The majority of the
women (n = 345, 67.3%; 95% CI 63.3–71.4) were not
sure if they had been vaccinated against measles during
childhood, 68 (13.2%; 95% CI 10.3–16.2) said that they
were vaccinated against measles and 99 (19.3%; 95% CI
15.9–22.8) answered that they had never been vaccinated
against measles at any point in their lives.
The mothers were divided in two groups by age criteria: a
group comprising women 29 years of age and older that
probably had acquired measles immunity through natural
infection, and a group including women 28 years of age
and younger that probably had measles vaccine-induced
immunity. The prevalence of measles IgG in these groups
of mothers was 89.2% (95% CI 83.7–94.7) and 80%
(95% CI 75.8–84.1), respectively. This difference was not
statistically significant (Pv>0.05). Moreover, there was no
association between the age of the mother and the pres-
ence of IgG among their offspring (Table 2).
Nutritional status
A great majority of the children enrolled in this study were
still breastfeeding (97.0%; 95% CI 95.2–98.2). The mean
birth weight was 3.064 grams (SD 450, range 1.900–
4.400)
No children with clinical malnutrition were observed.
Among the 211 infants aged six-months, 181 (85.7%;
95% CI 80.4–89.8), 185 (87.6%; 95% CI 82.5–91.4) and
151 (71.5%; 95% CI 65.1–77.2) children had more than
minus two Z-score for weight-for-height category, weight-
for-age category and height-for-age category, respectively.
Among the 301 infants aged nine-months, 219 (72.7%;
95% CI 67.4–77.4), 226 (75.0%; 95% CI 69.9–79.6) and
186 (61.7%; 95% CI 56.1–67.1) children had more than
minus two Z score for weight-for-height category, weight-
for-age category and height-for-age category, respectively.
We did not find any association between nutritional
parameters and the presence of measles-specific IgG in six-
and nine-month-old children (Table 2).
Premature and low-birth-weight children
Only about a third (36.5%; 95% CI 32.4–40.7) of the
mothers presented their last Pregnancy-Monitoring Card.
Based on card records, 127 (67.9%) of the babies had
been born at less than 37 weeks of gestation. All 512 chil-
dren had a Road-to-Health Card, but only 442 (86.3%;
95% CI 82.9–89.1) of the cards had the birth weight
recorded. Among 442 birth weight records, 58 (13.1%;
95% CI 10.1–16.7) indicated a child born with less than
2,500 grams.
We did not find any association between premature or
low-weight births and the presence of measles-specific IgG
in six- and nine-month-old children (Table 2).
Vaccine seroconversion
In a group of 198 nine-month-old children that returned
to the follow-up visit after vaccination, 52 were excluded
from this analysis because they were already positive for
IgG before vaccination. Among the remaining 146Page 4 of 8
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test for both antibody isotypes; we choose to test these
samples only for IgM antibody. Only 85 (58.2%; 95% CI
50.2–66.2) children had a positive test for measles-spe-
cific IgM while 37 (26.0%; 95% CI 18.8–33.2) became
positive for IgG. Among the 142 children tested for both
isotypes, 19 were positive for both IgG and IgM and 20
tested negative for both. Therefore, in this study, the sero-
conversion rate after measles immunization was 84.2%.
Gender, mother's age (categorically divided into those
born before and those after the introduction of EPI),
breast-feeding, history of measles, type of birth, low-birth-
weight, mother's immunity against measles (presence of
IgG antibody) and nutritional status in bivariate analysis
were not significantly associated with the presence of
measles-specific IgG/IgM antibodies after vaccination
(Table 2).
Discussion
Measles vaccination has proved to be an extremely suc-
cessful public health intervention and has already resulted
in the elimination of measles in selected areas of the globe
[2,22]. However, the success of measles immunization
depends on many factors, including the absence of mater-
nal antibodies at the time of vaccination [23]. Maternal
IgG is transferred via the placenta during the last trimester
of pregnancy and gradually wanes during first year of life
[23]. In many SSA countries measles immunization is
given at nine-months of age to avoid the interference of
passively acquired IgG.
In our study, 82.4% of the children aged six-months did
not have detectable levels of measles IgG in oral fluid. It is
possible that a proportion of these infants had low levels
of antibody only detectable in serum or by sensitive assays
such as the plaque reduction neutralization [24,25]. Still,
the oral fluid test used in our study identifies individuals
with protective levels of IgG [21]. In periods of wild virus
circulation, children identified as IgG-negative in this
study would be susceptible to measles for at least three
months before reaching the accepted age for vaccination.
In the period ranging from September 2004 (when the
oldest infant included in this study was born) and the end
of the study in September 2005, only sporadic measles
cases (41 and 53 reported cases in 2004 and 2005, respec-
tively) and no outbreak was observed in the study area
(Weekly Epidemiologic Bulletin, MoH Mozambique). How-
ever, a recent assessment of the routine surveillance sys-
tem in Maputo City has shown significant under-
reporting of measles [4]. In our study, measles virus circu-
Table 2: Risk indicators for the presence of immunoglobulin in the oral fluid from infants
Presence/absence of IgG in oral 
fluid at six months
Presence/absence of IgG in oral 
fluid before measles vaccination at 
nine months
Presence/absence of IgM & IgG in 
oral fluid after measles vaccination
Variable OR 95% CI OR 95% CI OR 95% CI
Gender (F, M) 1.1 0.74–1.61 1.1 0.78–1.55 0.66 0.32–1.37
Breast feeding 
(Yes, No)
1.02 1–1.04 0.88 0.39–1.95 2.73 0.62–1.20
Measles history 
(Yes, No)
1.39 0.17–11.43 0.78 0.14–4.28 0.22 0.01–3.70
Type of birth 
(Normal, 
Caesarean)
0.94 0.81–1.83 1.18 0.58–2.39 0.54 0.12–2.51
Low-birth-weight 
(Yes, No)
1.03 0.25–4.21 0.78 0.44–1.36 0.36 0.13–1.94
Prematurity 
(Yes, No)
1.02 0.7–1.48 0.57 0.31–1.05 1.70 0.54–3.35
Weight for height 
cat (≥ -2, <-2)
- - 0.78 0.32–1.87 1.18 0.12–1.01
Weight for age cat 
(≥ -2, <-2)
0.59 0.1–3.58 2.16 0.75–6.19 0.75 0.15–3.54
Height for age cat 
(≥ -2, <-2)
1.26 0.46–3.46 0.79 0.55–1.13 0.50 0.18–1.39
Mother's IgG 
(Pos, Neg*)
1.96 0.62–6.17 1.57 0.86–2.87 1.62 0.59–3.48
Mother's age ≤ 28 
y, ≥ 29 y
0.81 0.29–2.32 1.15 0.61–2.19 1.08 0.67–1.75
OR – Odds Ratio; Pv – chi-square P-value; F – female; M – male; IgG – Immunoglobulin type G; IgM – Immunoglobulin type M; Pos – Positive; Neg 
– Negative.Page 5 of 8
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onstrated in our setting by two-fold evidence: firstly, two
infants presented with measles specific IgM in oral fluid
and, secondly, a small proportion of children with mea-
sles specific IgG in oral fluid were born to mothers that
did not have detectable levels of measles IgG. However, as
none of the mothers recalled clinical episodes of measles-
like illnesses in their children, the exposure to wild-virus
probably only resulted in sub-clinical infections [26,27].
Further indirect evidence for sub-clinical measles in
infants comes from the fact that measles specific IgG was
present in a significantly higher proportion of nine-
month-old children when compared to six-month-old
children (30.5% vs. 12.3%, p < 0.001). In fact, recent
exposure to measles in some IgG-positive children was
self-evident due to the simultaneous presence of measles-
specific IgM. However, we can not exclude the possibility
of false positive test reactions among the nine-month
cohort. The impact of sub-clinical measles on the health
of unvaccinated young children or on vaccine-induced
immunity remains to be determined.
Premature birth, low-birth-weight and malnutrition were
not associated with the presence of immunoglobulin in
oral fluid from infants (Table 2). We found a relatively
high proportion of children with less than minus two z-
scores on nutrition parameters. It has been previously
documented that international nutritional and growth
evaluation scales may not be appropriate for recourse-
poor, tropical areas of the world [28]. Mounting evidence
points out that this apparent state of reduce growth does
not affect the physical activity of the individuals living in
the tropics [28]. Nevertheless, the consequences of this
growth and nutritional status on the physiology of the
immune system require further research. Surprisingly,
68% of the children included in this study were born at
less than 37 weeks of gestation. This information, based
on the last menstrual cycle date provided by the mother,
was collected from the Pregnancy-Monitoring Card and is
known to be of low accuracy [29,30].
We expected that mothers aged 28 years and younger,
believed to have vaccine-induced immunity, would give
birth to offspring with a wider "window of susceptibility"
than mothers with immunity from natural infection
[31,32]. Two situations may explain why this is not the
case in our setting (Table 2). First, periodic measles out-
breaks in Maputo City may have provided opportunities
for immunity boosters in all women and eliminated the
classical picture of lower antibody levels in vaccinated
women. We were not able to verify this finding because
the oral fluid test for measles IgG is not a quantitative
assay. Second, the IgG present in children may have
resulted from exposure to wild-virus after complete wan-
ing of maternal IgG. The cross-sectional design of our
study and the lack of laboratory assays that can differenti-
ate between antibodies derived from natural infection as
opposed to vaccination limited further investigation of
these questions.
Success of vaccination at the individual level can be meas-
ured by the resulting immune response. We investigated
seroconversion after immunization by measuring mea-
sles-specific IgG and IgM in oral fluid. In Maputo City, the
cold chain is well monitored and follows the interna-
tional WHO standards. Our study showed that 84.2% of
the children developed an immune response with measles
specific IgG and IgM detectable in oral fluid. While the use
of more sensitive serum or plasma testing may have
shown a slightly higher rate of seroconversion [33], the
observed rate in our study can be considered as satisfac-
tory when compared to the minimum acceptable serocon-
version rate of 85% [34].
This study did not find any factor significantly associated
with seroconversion after vaccination. We can not exclude
the possibility that low levels of IgG, that were undetecta-
ble in oral fluid but that could modulate the immune
response against the vaccine, played a role in determining
the observed rate of seroconversion [35]. As some of the
evidence presented in this study suggests, measles anti-
bodies can arise from exposure to wild-virus among
unprotected children. We did not investigate the role of
HIV infection in the immune response of vaccinated chil-
dren. It is possible that primary and secondary measles
vaccine failures in HIV infected children play a role in
maintaining the circulation of wild-type virus in Mozam-
bique [36]. Although the impact of the HIV epidemic
should be taken in consideration when updating measles
immunization policy, it is unlikely that countries will
adopt different measles immunization policies aimed at
HIV-infected children.
The oral fluid tests for measles-specific IgG and IgM used
in this study constitute a good alternative to serum/
plasma assays for epidemiological surveys as invasive
specimen collection is avoided and samples may be stored
for up to 21 days at room temperature [16,21]. The main
limitations of these tests are posed by difficulties in
obtaining sufficient volumes of oral fluid from infants
and by the relatively low sensitivity and specificity of the
IgG assay. Indeed, it may be possible that the 12 IgG pos-
itive infants born to IgG negative mothers represent false-
positive results. However, this is unlikely as five of these
children were also IgM positive, further supporting our
hypothesis that children are exposed to wild-type measles
virus. It is also not likely that the higher prevalence of
measles IgG in nine months old children is due to a higher
rate of false-positive results in this age group.Page 6 of 8
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this is now routinely used in the MMR reference labora-
tory in the United Kingdom. In 2008, Vainio et al. [37]
recommended the testing of oral fluid specimens using
the MicroImmune assay for measles surveillance in Nor-
way.
Measles virus circulation continues to occur in SSA even
though many of countries have increased the routine vac-
cination coverage. An assessment of the surveillance sys-
tem in Mozambique showed that in Maputo City during
1998 measles vaccine coverage was 85% and measles
attack rate in children less than nine-months of age was
about 24 per 10,000 inhabitants [4]. In three outbreaks
studied in 1998 and 2002, children under nine-months of
age accounted for between 11.1% and 22.2% of all
reported measles cases [4], a proportion similar to the one
observed in communities where immunization has not
been introduced [38]. These epidemiological observa-
tions are in line with our biological findings that, in most
children, passive immunity against measles wanes well
before immunization takes place. Therefore, for countries
like Mozambique, efforts to narrow the window of sus-
ceptibility should be regarded as important as those
directed towards cutting the circulation of wild virus
through increasing the coverage of routine and supple-
mentary vaccination.
Conclusion
The introduction of a fixed two-dose immunization
schedule may be necessary if the window of susceptibility
is to be reduced. One possibility is to vaccinate before
nine-months of age and provided a second dose at a later
age. The lower prevalence of measles IgG in six-month-old
children living in Maputo City shows that these infants
seem to be susceptible to measles three months before the
recommended age of vaccination. This study enlighten
some of the problems related to measles vaccination
schedule but does not bring enough evidence to advise
change of vaccination policy without further investiga-
tions.
The road to measles elimination in SSA is paved with sev-
eral biological and non-biological determinants. While
studies continue investigate relevant scientific questions
and evaluate the cost-effectiveness and feasibility of
adjustments in the measles immunization schedule,
efforts should continue to focus on increasing the cover-
age of the EPI and introduction of supplementary vaccina-
tion.
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